01 Shift toward Decentralized Clinical Trials (dcts) The shift towards decentralized clinical trials (DCTs) is a major trend for the outsourcing market. DCTs leverage digital health technologies to conduct trials remotely, allowing patients to participate from the comfort of their homes. This approach enhances patient recruitment and retention, reduces geographic barriers, and improves the overall patient experience. For instance, around 1,300 trials with a decentralized and virtual component were initiated in 2022, representing a 28% increase from 2021. This market trend is driving demand for CROs that specialize in managing decentralized trials as companies seek external expertise to navigate the complex logistics and regulatory requirements of this new approach.
February 2026 ICON expanded its clinical trial technology capabilities through enhanced decentralized clinical trial solutions, integrating digital health technologies, remote monitoring, and patient engagement platforms to improve global trial execution.
January 2026 Thermo Fisher Scientific expanded its clinical research services portfolio through new investments in clinical trial supply chain capabilities, strengthening its ability to support complex global studies.
October 2025 Parexel expanded its clinical trial operations network with additional technology-enabled solutions focused on improving patient recruitment, site management, and decentralized trial execution.
August 2025 IQVIA expanded its AI-powered clinical development solutions, introducing advanced analytics and automation capabilities to support faster trial design, patient identification, and clinical data management.